盟科藥業(688373.SH)2022年度預虧2億至2.5億元
格隆匯1月19日丨盟科藥業(688373.SH)公佈,預計2022年年度實現營業收入約4700萬元到5000萬元,與上年同期相比,將增加3934萬元到4234萬元,同比去年增長513.58%至552.74%。
預計2022年度歸屬於上市公司股東的淨利潤約-2.5億元到-2億元,同比去年上下浮動在15%以內。
預計2022年度歸屬於上市公司股東的扣除非經常性損益後的淨利潤約為-3億元到-2.5億元,同比去年上下浮動在15%以內。
報吿期內,公司主營產品康替唑胺片進入國家醫保,提升了醫患人員對該藥品的認可和可及性。公司持續佈局商業化銷售渠道,擴大醫藥商業公司分銷網絡,增加終端醫院覆蓋,加大學術推廣力度,因此主營業務收入實現快速增長。
雖然報吿期內公司收入實現增長,但公司大多數新藥研發產品管線仍處於臨牀前或臨牀研發階段,研發費用投入依然保持在較高水平。同時,隨着公司業務的發展,報吿期內銷售費用、管理費用也有所上升。總體使得公司淨利潤在報吿期繼續維持虧損狀態。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.